At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
BMS-986012 (anti-fucosyl-GM1) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating BMS-986012 (anti-fucosyl-GM1) and Nivolumab for Small Cell Lung Cancer. Completed, enrolled 106 participants across 16 sites in 7 countries.
Detailed Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesAustralia, Belgium, Canada, Netherlands, Puerto Rico, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartNov 2014
Primary CompletionDec 2022
Study CompletionDec 2022
TodayJul 2026
First PostedSep 25, 2014
Enrollment StartNov 14, 2014
Primary CompletionDec 21, 2022
Study CompletionDec 22, 2022
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 11.8 years ago
Interventions
BMS-986012 (anti-fucosyl-GM1)biological
Nivolumabbiological